---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-099044"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2022-04-07T23:59:59+00:00"
generated_at: "2026-06-26T08:53:14.043531+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics enters $15M upfront license deal with Jazz for WTX-613 (IFNα INDUKINE)

## Summary
- Upfront payment of $15M within 10 days of signing; Jazz to reimburse pre-clinical costs.
- Eligible for up to $520M in development/regulatory milestones and up to $740M in sales-based milestones.
- Tiered mid-single-digit royalties on annual net sales of licensed products.
- Werewolf grants Jazz worldwide exclusive license to patent rights for IFNα variants, including WTX-613.
- Jazz responsible for IND submission and all subsequent development and commercialization.

## SEC filing metadata
- accession: 0001193125-22-099044
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2022-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000119312522099044/0001193125-22-099044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000119312522099044/d335484d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-099044
- JSON: https://secwatch.observer/filing/0001193125-22-099044.json
- Plain text: https://secwatch.observer/filing/0001193125-22-099044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.